Market Place
Sourcing Support
SIRPant to Participate in Wells Fargo Virtual Biotech Symposium
30 Apr 2024 //
GLOBENEWSWIRE
SIRPant Announces First Patient Dosed in Phase 1 Evaluating SIRPant-M
12 Mar 2024 //
GLOBENEWSWIRE
SIRPant Strengthens Board of Directors with Appointment of Roger Sawhney, M.D.
22 Jan 2024 //
GLOBENEWSWIRE
SIRPant Announces FDA Clearance of IND Application for SIRPant-MTM
12 Dec 2023 //
GLOBENEWSWIRE
SIRPant Immunotherapeutics Receives FDA Orphan Drug Designation for SIRPant-M
15 Nov 2023 //
GLOBENEWSWIRE
SIRPant Immunotherapeutics to Present Trial in Progress Poster at Annual Meeting
27 Sep 2023 //
GLOBENEWSWIRE
SIRPant Immunotherapeutics Appoints Jelle Kijlstra as Chief Medical Officer
11 Jul 2023 //
BUSINESSWIRE
FDA clears SIRPant IND to start Phase I non-Hodgkin lymphoma therapy trial
02 May 2023 //
CLINICAL TRIALS ARENA
SIRPant Immunotherapeutics Announces FDA Clearance of IND for SIRPant-
01 May 2023 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.